DUBLIN, Sept. 25, 2015 /PRNewswire/ -- Allergan plc
(NYSE: AGN), a leading global pharmaceutical company, today
announced that it has launched a generic version of Janssen's
INVEGA® (paliperidone extended-release tablets) in the
U.S. Allergan is the first company to receive FDA approval
for and launch a generic version of INVEGA®,
demonstrating the deep expertise of the Company's global
generics R&D, regulatory and supply chain teams.
Logo- http://photos.prnewswire.com/prnh/20150612/222796LOGO
"This launch reinforces Allergan's commitment to developing,
manufacturing and bringing to market high-quality, affordable
versions of challenging products like INVEGA®,
benefiting patients and reducing healthcare costs," said
Robert Stewart, Allergan's Executive
Vice President & President, Generics and Global Operations.
INVEGA® extended-release tablets are indicated for
the treatment of schizophrenia in adults and adolescents (12-17
years of age).
For the 12 months ended July 31,
2015, INVEGA® had total U.S. brand sales of
approximately $612 million, according
to IMS Health data.
About Allergan
Allergan plc (NYSE: AGN),
headquartered in Dublin, Ireland,
is a unique, global pharmaceutical company and a leader in a new
industry model – Growth Pharma. Allergan is focused on
developing, manufacturing and commercializing innovative branded
pharmaceuticals, high-quality generic and over-the-counter
medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that
provide valuable treatments for the central nervous system, eye
care, medical aesthetics, gastroenterology, women's health,
urology, cardiovascular and anti-infective therapeutic categories,
and operates the world's third-largest global generics business,
providing patients around the globe with increased access to
affordable, high-quality medicines. Allergan is an industry leader
in research and development, with one of the broadest development
pipelines in the pharmaceutical industry and a leading position in
the submission of generic product applications globally.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives.
For more information, visit Allergan's website at
www.allergan.com.
Forward-Looking Statements
Statements contained
in this press release that refer to future events or other
non-historical facts are forward-looking statements that reflect
Allergan's current perspective of existing trends and information
as of the date of this release. Except as expressly required by
law, Allergan disclaims any intent or obligation to update these
forward-looking statements. Actual results may differ materially
from Allergan's current expectations depending upon a number of
factors affecting Allergan's business. These factors include, among
others, the risks associated with acquisition transactions; the
difficulty of predicting the timing or outcome of FDA approvals or
actions, if any; the impact of competitive products and pricing;
market acceptance of and continued demand for Allergan's products;
difficulties or delays in manufacturing; and other risks and
uncertainties detailed in Allergan's periodic public filings with
the Securities and Exchange Commission, including but not limited
to Allergan's Quarterly Report on Form 10-Q for the quarter ended
June 30, 2015 (such periodic public
filings having been filed under the "Actavis plc" name) and from
time to time in Allergan's other investor communications . Except
as expressly required by law, Allergan disclaims any intent or
obligation to update these forward-looking statements.
CONTACTS:
Allergan:
Investors:
Lisa DeFrancesco
(862) 261-7152
Media:
Mark Marmur
(862) 261-7558
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/allergan-launches-generic-version-of-invega-paliperidone-300148943.html
SOURCE Allergan plc